Sex differences in urinary levels of several biological indicators of exposure: A human volunteer study

Toxicology Letters

Volumn 202, Issue 3, 2011, Pages 218-225

  Tomicic, Catherine ^a   Berode, Michèle ^a   Oppliger, Anne ^a   Castella, Vincent ^b   Leyvraz, Fabienne ^b   Praz Christinaz, Sophie Maria ^a   Danuser, Brigitta ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

Author keywords

Biological indicators of exposure; Human biomonitoring; Organic solvents; Sex differences; Toxicokinetics

Indexed keywords

1 METHOXY 2 PROPANOL; 1,1,1 TRICHLOROETHANE; 2 BUTANONE; BIOLOGICAL MARKER; CYTOCHROME P450 2E1; PROPANOL; SOLVENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; BUTANONES; CONTRACEPTIVES, ORAL, HORMONAL; CYTOCHROME P-450 CYP2E1; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FEMALE; GENOTYPE; HUMANS; MALE; OCCUPATIONAL DISEASES; POLYMORPHISM, GENETIC; PROPYLENE GLYCOLS; QUESTIONNAIRES; SEX FACTORS; SOLVENTS; TRICHLOROETHANES; YOUNG ADULT;

EID: 79954600386     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.01.032     Document Type: Article

References (45)

1. Arbuckle T.E. Are there sex and gender differences in acute exposure to chemicals in the same setting?. Environ. Res. 2006, 101:195-204.
2. Baker E.L. Organic solvent neurotoxicity. Annu. Rev. Public Health 1988, 9:223-232.
3. Baker M.E. Albumin, steroid hormones and the origin of vertebrates. J. Endocrinol. 2002, 175:121-127.
4. Bebia Z., Buch S.C., Wilson J.W., Frye R.F., Romkes M., Cechetti A., Chaves-Gnecco D., Branch R.A. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin. Pharmacol. Ther. 2004, 76(6):618-627.
5. Bjørnerem A., Straume B., Midtby M., Fønnebø V., Sundsfjord J., Svartberg J., Acharya G., Øian P., Berntsen G.K.R. Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromsø study. J. Clin. Endocrinol. Metab. 2004, 89(12):6039-6047.
6. Bolt H.M., Roos P.H., Their R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int. Arch. Occup. Environ. Health 2003, 76:174-185.
7. Breimer D.D., Ketelaars H.C.J., Van Rossum J.M. Gas chromatographic determination of choral hydrate, trichloroethanol and trichloroacetic acid in blood and urine employing head-space analysis. J. Chromatogr. 1974, 88:55-63.
8. Cai L., Zheng Z.L., Zhang Z.F. Cytochrome p450 2E1 polymorphisms and the risk of gastric cardia cancer. World J. Gastroenterol. 2005, 11(12):1867-1871.
9. Caperos J.R., Droz P.O., Hake C.-L., Humbert B.E., Jacot-Guillarmod A. 1,1,1-Trichloroethane exposure, biologic monitoring by breath and urine analyses. Int. Arch. Occup. Environ. Health 1982, 49(3-4):293-303.
10. Clewell H.J., Teeguarden J., McDonald T., Sarangapani R., Lawrence G., Covington T., Gentry R., Shipp A. Review and evaluation of the potential impact of age- and sex-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 2002, 32(5):329-389.
11. Devanthéry A., Dentan A., Berode M., Droz P.O. Propylene glycol monomethyl ether (PGME) exposure. I. Biomonitoring by analysis of PGME in urine. Int. Arch. Occup. Environ. Health 2000, 73:311-315.
12. Devanthéry A., Berode M., Droz P.O. Propylene glycol monomethyl ether occupational exposure. 3. Exposure of human volunteers. Int. Arch. Occup. Environ. Health 2002, 75(4):203-208.
13. Droz P.-O., Boillat M.-A., Berode M., Lob M. Surveillance de l'exposition aux solvants. Présentation d'une étude en cours. Int. J. Public Health 1983, 28:254-255.
14. Droz P.-O., Guillemin M.P. Occupational exposure monitoring using breath analysis. J. Occup. Med. 1986, 28(8):593-602.
15. Droz P.-O. Quantification of biological variability. Ann. Occup. Hyg. 1992, 36:295-306.
16. Ernstgård L., Gullstrand E., Löf A., Johanson G. Are women more sensitive than men to 2-propanol and m-xylene vapours?. Occup. Environ. Med. 2002, 59(11):759-767.
17. Ernstgård L., Sjögren B., Warholm M., Johanson G. Sex differences in the toxicokinetics of inhaled solvent vapors in humans. 1. m-Xylene. Toxicol. Appl. Pharmacol. 2003, 193:147-157.
18. Ernstgård L., Sjögren B., Warholm M., Johanson G. Sex differences in the toxicokinetics of inhaled solvent vapors in humans. 2. 2-Propanol. Toxicol. Appl. Pharmacol. 2003, 193:158-167.
19. Gandhi M., Aweeka F., Greenblatt R.M., Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. Annu. Rev. Pharmacol. 2004, 44:499-523.
20. Gochfeld M. Framework for gender differences in human and animal toxicology. Environ. Res. 2007, 104(1):4-21.
21. Imbriani M., Ghittori S. Gases and organic solvents in urine as biomarkers of occupational exposure: a review. Int. Arch. Occup. Environ. Health 2004, 78(1):1-19.
22. Kennedy M.J. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin. Pharmacol. Ther. 2008, 84:662-673.
23. Löf A., Johanson G. Toxicokinetics of organic solvents: a review of modifying factors. Crit. Rev. Toxicol. 1998, 28(6):571-650.
24. Meibohm B., Beierle I., Derendorf H. How important are sex differences in pharmacokinetics?. Clin. Pharmacokinet. 2002, 41(5):329-342.
25. Messing K., Mergler D. Introduction: women's occupational and environmental health. Environ. Res. 2006, 101:147-148.
26. Messing K., Stellman J.M. Sex, gender and women's occupational health: the importance of considering mechanism. Environ. Res. 2006, 101:149-162.
27. Miners J.O., Attwood J., Birkett D.J. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br. J. Clin. Pharmacol. 1983, 16(5):503-509.
28. Nakajima T., Wang R.S., Elovaara E., Gonzalez F.J., Gelboin H.V., Raunio H., Pelkonen O., Vainio H., Aoyama T. Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem. Pharmacol. 1997, 53(3):271-277.
29. Nicolson T.J., Mellor H.R., Roberts R.R. Gender differences in drug toxicity. Trends Pharmacol. Sci. 2010, 31(3):108-114.
30. Panzer C., Wise S., Fantini G., Kang D., Munarriz R., Guay A., Goldstein I. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J. Sex Med. 2006, 3(1):104-113.
31. Parkinson A., Mudra D.R., Johnson C., Dwyer A., Carroll K.M. The effects of sex, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 2004, 199:193-209.
32. Pierrehumbert G., Droz P.O., Tardif R., Charest-Tardif G., Truchon G. Impact of human variability on the biological monitoring of exposure to toluene, phenol, lead, and mercury. II. Compartimental based toxicokinetic modelling. Toxicol. Lett. 2002, 134:165-173.
33. Prieto-Castelló M.J., Cardona A., Marhuenda D., Roel J.M., Corno A. Use of the CYP2E1 genotype and phenotype for the biological monitoring of occupational exposure to styrene. Toxicol. Lett. 2010, 192(1):34-39.
34. Pugeat M., Nader N., Hogeveen K., Raverot G., Déchaud H., Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol. Cell. Endocrinol. 2009, 316(1):53-59.
35. Sato A., Endoh K., Kaneko T., Johanson G. A simulation study of physiological factors affecting pharmacokinetic behaviour of organic solvent vapours. Br. J. Ind. Med. 1991, 48:342-347.
36. Scandlyn M.J., Stuart E.C., Rosengren R.J. Sex-specific differences in CYP450 isoforms in humans. Expert Opin. Drug Metab. Toxicol. 2008, 4(4):413-424.
37. Schwartz J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 2003, 42(2):107-121.
38. Sedivec V., Mraz M., Flek J. Biological monitoring of persons exposed to methanol vapours. Int. Arch. Occup. Environ. Health 1981, 48:257-271.
39. Sethre T., Läubli T., Berode M., Krueger H. Neurobehavioural effects of experimental isopropanol exposure. Int. Arch. Occup. Environ. Health 2000, 73:105-112.
40. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J. Clin. Pharmacol. Ther. 1998, 23(4):247-255.
41. Tardif R., Droz P.-O., Charest-Tardif G., Pierrehumbert G., Truchon G. Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. Toxicol. Lett. 2002, 134(1-3):155-163.
42. Thompson C.M., Johns D.O., Sonawane B., Barton H.A., Hattis D., Tardif R., Krishnan K. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J. Toxicol. Environ. Health B 2010, 12(1):1-24.
43. Tomicic C., Berode M. Sensitive headspace gas chromatography analysis of free and conjugated 1-methoxy-2-propanol in urine. Anal. Bioanal. Chem. 2010, 396(7):2367-2721.
44. Tomicic C., Droz P.-O., Berode M., Praz Christinaz S.M., Castella V., Danuser B. P101-007 controlled human exposures to organic solvents: influence of sex on urinary levels of biological indicators. Toxicol. Lett. 2010, 196S:39.
45. Truchon G., Tardif R., Droz P.-O., Charest-Tardif G., Pierrehumbert G. Biological exposure indicators: quantification of biological variability using toxicokinetic modeling. J. Occup. Environ. Hyg. 2006, 3(3):137-143.